RAPT THERAPEUTICS INC (RAPT)
US75382E1091 - Common Stock
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status - Confirmed ORR of 17.4% in subset of patients with...
3 Biotech Stocks to Dump Before They Go to Zero
These biotech stocks to sell are burning through cash at an alarming rate and seem destined for zero, making them prime targets for selling.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT). Such...
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips RAPT Therapeutics (NASDAQ:RAPT) just reported results for the fourth quarter of...
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Company maintains solid cash position of $158.9 million
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Company maintains solid cash position of $158.9 million...
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT). Such...
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
H.C. Wainwright cuts RAPT to neutral, cites delays due to clinical hold (NASDAQ:RAPT)
H.C. Wainwright has downgraded RAPT Therapeutics (RAPT) to neutral, stating that clinical development of the company’s drug zelnecirnon may be delayed more than
J.P. Morgan cuts RAPT to neutral, recommends against buying dip (NASDAQ:RAPT)
J.P. Morgan has downgraded RAPT Therapeutics (RAPT) to neutral, stating that it can’t recommend buying the dip in price due to uncertainty surrounding the compa
Notable Tuesday Option Activity: BCPC, STNG, RAPT
Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests
The FDA put studies in eczema and asthma treatment on clinical hold.
RAPT stock craters after FDA puts clinical hold on dermatitis drug (NASDAQ:RAPT)
Shares of RAPT Therapeutics (RAPT) cratered 64% in early trading Tuesday after the biotech company said the FDA had placed a clinical hold on two Phase 2 clinic
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
- RAPT to host a conference call today at 8:30 am ET - SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq:...
Evercore ISI starts RAPT at outperform, cites upcoming Phase 2b data (NASDAQ:RAPT)
Evercore ISI has started coverage of RAPT Therapeutics (RAPT) with an outperform rating, citing upcoming data for the company’s atopic dermatitis drug. Read more here.
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Notable Wednesday Option Activity: SPGI, RAPT, SLG